
ææªãªã®ã¯ããããïŒCOVID Spike Proteinsãå åæ³ç³»ãåŸã ã«å·ã€ãããã«ã¢ã³é¢é£çŸæ£ã®å¢å ãèŠå
å èšäºã¯ãã¡ã/Original article here
ãã©ãžã«ã®å åæ³åŠè ãã©ããªã»ã«ããžã¢ãŒãå士ã¯ãã¹ãã€ã¯ç¶ã®ã¿ã³ãã¯è³ªãåŒãèµ·ããå åæ³ç³»ã®ç æ°ã¯ããŸã ææªã®äºæ ãè¿ããŠããªãã®ã§ã¯ãªãããšèããŠããã
å åæ³ç³»ã¯ãä¿ã«ãã«ã¢ã³ç³»ãšåŒã°ããç§ãã¡ã®å¥åº·ã«ãšã£ãŠæ¥µããŠéèŠã§ããããã«ã¢ã³ã®åæ³ã«ãã£ãŠãæé·ã»çºéãæ°åã代è¬ãçæ®ãå ç«ããã®ä»ã®èåšã®æ©èœã調ç¯ããŠããã
ãã«ã¢ã³ã¯ãäœå ã®3倧ã¡ãã»ã³ãžã£ãŒã®äžã€ã§ããä»ã®2ã€ã®ã¡ãã»ã³ãžã£ãŒã§ããç¥çµäŒéç©è³ªãšãµã€ãã«ã€ã³ã«æ¯ã¹ããã«ã¢ã³ã¯åå¿ãé ãã屿çãªäœçšã§ã¯ãªããäœå šäœã«åã¶å šèº«çãªæ©èœãæããŠããŸãã
éåžžãç¥çµäŒéç©è³ªã«ã¯ããªç§ããµã€ãã«ã€ã³ã«ã¯æ°åããæ°æéã§åå¿ããã®ã«å¯Ÿãããã«ã¢ã³ã«åå¿ãã现èã¯æ°æéããæ°é±éãããããšããããŸãã
ãã«ã¢ã³ã¯ãã£ãããšå šèº«ã«äœçšãããããå åæ³ç³»ã«æ©èœäžå šãé害ããããšãäžè¬ã«çç¶ã®çºçŸãååŸ©ã«æéããããã
COVID-19ææãã¯ã¯ãã³ã«ããã¹ãã€ã¯ç¶ã®ã¿ã³ãã¯è³ªããäžåäœãç²ç¶è ºãå¯è ãçæ®åšãªã©å€ãã®å åæ³è ºãæå·ããããšãç ç©¶ã§æããã«ãªã£ãŠããã
Cadegianiã¯ãå åæ³ç³»ã®ç æ ã¯çºçãé ãããã蚺æãæ²»çã«å°é£ã䌎ãã®ã§ã¯ãªãããšæžå¿µããŠããã
ãã«ã¢ã³ã®è²¯èµéã®æžå°
å åæ³è ºã«ã¯ "äºåèœ "ããããããå åæ³ã®ç æ ãæããã«ãªããŸã§ã«ã¯æéãããããšãCadegianiã¯èšãã
ãå åæ³è ºã«ã¯äºåèœããããäºåèœã®æžå°ã¯ä»ããã«ã¯èšåºçã«ç¢ºèªã§ããªãããå°æ¥çã«ã¯ç¢ºèªã§ãããããããªãããšããããªãå·ãã·ããŒã®Front Line COVID-19 Critical Care Allianceã§Cadegianiã¯è¿°ã¹ãŠããã
ãã®ããã眹æ£è ã¯èãããªããªããŸã§çç¶ãçŸããªãããšãããã
Cadegianiæ°ã¯ãå°æ¥ãžã®æžå¿µã®ã»ãšãã©ã¯ã圌èªèº«ã®èšåºèгå¯ã«åºã¥ãæ¶æž¬ã§ãããšè¿°ã¹ãããããããã³ãããã¯ãšCOVID-19ã¯ã¯ãã³ã®æäžãå§ãŸã£ãŠä»¥æ¥ãå åæ³ç³»ã®ç æ ã瀺åããå ±åãå¢ããŠããŠããã
ãã«ã¢ã³è»žãšå šèº«ã®æ©èœé害
ãã«ã¢ã³ã¯å šèº«ã調ç¯ããŠããã®ã§ããã£ããäºåè»ãæ¯æžããæ ¹æ¬çãªå åæ³ã®ç æ ãæããã«ãªããšãå šèº«ã®èª¿ç¯äžå šã«é¥ãã±ãŒã¹ããããŸãã
å åæ³è ºã¯ãå šèº«ã®å€ãã®èåšã®æ©èœãå¶åŸ¡ããŠãããåå åæ³åšå®ã¯ããã«ã¢ã³è»žãšãåŒã°ãããã£ãŒãããã¯ã«ãŒãã§ã€ãªãã£ãŠããŸãã
ãã®é£éã®é ç¹ã«ããã®ãèŠåºäžéšã§ããèŠåºäžéšã¯è³ã®äžã«ãããã€ã€ã¢ã³ãã®ãããªæ§é ã§ããã¹ã¿ãŒã¹ã€ããããŒããšããŠæ©èœããŠããŸããèŠåºäžéšã¯ã錻ã®å¥¥ã«ããå°ããªæ¥ååœ¢ã®æ§é ç©ã§ããäžåäœã«ã¡ãã»ãŒãžãéããŸãã
äžåäœã¯ä¿ã«ãã¹ã¿ãŒã°ã©ã³ããšåŒã°ããèŠåºäžéšãšãšãã«ãã«ã¢ã³è»žã圢æããä»ã®å åæ³åšå®ã調ç¯ããŠããŸãã
äžåäœã¯èŠåºäžéš-äžåäœ-æ§è ºïŒHPGïŒè»žã®äžéšã§ãåµå·£ã粟巣ãªã©ã®çæ®åšå®ã調ç¯ããŠããŸãã女æ§ã§ã¯æçµåšæã®äžéšãšããŠåµå·£ãã«ã¢ã³ã®æŸåºã調ç¯ãã圹å²ãæ ããç·æ§ã§ã¯ãã®è»žã粟å圢æã調ç¯ããŠããŸãã
èŠåºäžéš-äžåäœ-å¯è ïŒHPAïŒè»žã¯ãå¯è ãåªä»ããç¥çµå åæ³è»žã§ãããéäºãŸãã¯éèµ°åå¿ãåŒãèµ·ãããã«ã¢ã³ãç£çããåšå®ã§ããã
éäºãŸãã¯éèµ°ã®ããã»ã¹ã¯ãæå®³ãªè åšã«åå¿ããŠèµ·ããã¹ãã¬ã¹åå¿ã§ããã代è¬ãäœäžãããå ç«ãæå¶ããã ãã§ãªãã亀æç¥çµç³»ã掻æ§åãããããšããããŸãã
ããã²ãšã€ã®äž»èŠãªè»žã¯ãèŠåºäžéš-äžåäœ-ç²ç¶è ºè»žã§ããããã¯ãç²ç¶è ºãšãã®åæ³ãããã«ã¢ã³ã調ç¯ããŠããŸããç²ç¶è ºãã«ã¢ã³ã¯ãæé·ã埪ç°åšç³»ã®èª¿ç¯ã骚ã®çœ®æãèæ©èœã代è¬ãªã©ã®çç©åŠçæ©èœã«äžå¯æ¬ ã§ããã
ã¹ãã€ã¯èçœãå åæ³ç³»ãã¿ãŒã²ããã«ããä»çµã¿
ã¹ãã€ã¯èçœã¯SARS-CoV-2ãŠã€ã«ã¹ã®äžã§æãæ¯æ§ã®åŒ·ãéšåã§ãããé·ãCOVID-19ãšã¯ã¯ãã³æ¥çš®åŸã®çç¶ãæã€äººã ã«é¢ããç ç©¶ã§ã¯ããã°ãã°æé²åŸæ°ã¶æãããã¯1幎åŸã«ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ååšãæ€åºãããŠããã
ã¹ãã€ã¯èçœã¯ãACE2ããã³CD147ã¬ã»ãã¿ãŒãçºçŸããŠããçµç¹ãåšå®ãç¹ã«å¥œããèµèãç²ç¶è ºã粟巣ãåµå·£ãå¯è ãäžåäœãªã©ãå€ãã®å åæ³è ºãACE2å容äœãçºçŸããŠãããå åæ³ç³»ã¯ç¹ã«SARS-CoV-2ã«è匱ãªå Žæãšãªã£ãŠããŸãã
ã¹ãã€ã¯ã¿ã³ãã¯ã«ããçŸæ£ã®äž»ãªèŠå ã¯ãççã§ãã
ã¹ãã€ã¯ã¿ã³ãã¯ã¯çްèå ã«äŸµå ¥ãããšãDNAæå·ã®èªçºãDNA修埩ã®é»å®³ã现èã®ãšãã«ã®ãŒç£çã«éèŠãªããã³ã³ããªã¢ãžã®ã¹ãã¬ã¹ãªã©ãççæ§çµè·¯ã掻æ§åãããŸãããããã¯ãã¹ãŠã现èã®ã¹ãã¬ã¹ãå·å®³ããããŠçŽ°èæ»ã®å¯èœæ§ã«ã€ãªããã
å€ãã®çްèã圱é¿ãåãããšãçµç¹ãèåšã«åé¡ãçããåã ã®å åæ³è ºãã·ã¹ãã ã«ã圱é¿ãåãŒãå¯èœæ§ããããŸãã
ã¹ãã€ã¯ã¿ã³ãã¯ã¯ãŸãã现èã®ããªãµã€ã¯ã«ã·ã¹ãã ãã§ãããªãŒããã¡ãžãŒãé»å®³ããããã现èãæå®³ãªã¿ã³ãã¯è³ªãæé€ããããšãã§ãããé害ãé·åŒãããšã«ãªããŸãã
ã¹ãã€ã¯ã¿ã³ãã¯ã¯ãèªå·±å ç«ã«ãé¢äžããŠããå¯èœæ§ããããŸããããã®äžè¬çãªçµç¹ãã¿ã³ãã¯è³ªãšå€ãã®é¡äŒŒæ§ãæã£ãŠããããããååæš¡å£ããšåŒã°ããå ç«çްèãèªåèªèº«ã®çްèãèåšã«å¯ŸããŠæ»æã仿ããå åæ³é害ã«ã€ãªããå¯èœæ§ãããã®ã ã
COVID-19ã¯ã¯ãã³æ¥çš®åŸã®å åæ³é害ã«ã€ããŠã¯ãããã€ãã®ç ç©¶ã§å ±åãããŠããããæ£ç¢ºãªé害ã«ã€ããŠã®ããŒã¿ã¯ãŸã åºãŠããŠããªãã
äžåäœ
äžåäœã¯å åæ³ç³»ã®ãã¹ã¿ãŒè ºãšããŠãä»ã®å åæ³è ºãå¶åŸ¡ãããã«ã¢ã³ãå«ãå€ãã®ãã«ã¢ã³ãåæ³ããŠããŸãã
å¯è ç®è³ªåºæ¿ãã«ã¢ã³ïŒACTHïŒã¯ãå¯è ãæšçãšããŠãã¹ãã¬ã¹åå¿ãåºæ¿ããã³ã«ããŸãŒã«ã®ç£çã«é¢äžããŠããŸãã
ç²ç¶è ºåºæ¿ãã«ã¢ã³ïŒTSHïŒã¯ãç²ç¶è ºã調ç¯ããã
æé·ãã«ã¢ã³ã¯ãæé·ãšä»£è¬ãåžãã
ã¡ã©ããµã€ãåºæ¿ãã«ã¢ã³ã¯ã玫å€ç·ã济ã³ããšã¡ã©ãã³ã®çæãä¿é²ãã飿¬²ãå¢é²ãããã
æå©å°¿ãã«ã¢ã³ã¯ãæ°Žåãä¿æããå°¿ã®éãå°ãªãããåãããããŸãã
é»äœåœ¢æãã«ã¢ã³ïŒLHïŒãåµèåºæ¿ãã«ã¢ã³ïŒFSHïŒãããã©ã¯ãã³ã¯ãçæ®ã«éèŠãªåããããŸãã
ãªãã·ãã·ã³ã¯ãåºç£ãæ°é³ä»£è¬ãå¹žçŠæã«é¢äžããã
现èå¹é€ã§ã®ç ç©¶ã«ãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯äžåäœçްèã®LHããã³FSHã®ç£çãæå¶ããããšãæããã«ãªã£ãŠããŸãããããã«ãããé·æçãªåœ±é¿ã¯äžæã§ãã
æ¥æ¬ã§ã¯mRNAã¯ã¯ãã³æ¥çš®åŸã«ACTHæ¬ ä¹çã芳å¯ãããŠããã眹æ£è ã¯äžåäœãçž®å°ããŠããããšã倿ããŠããã
Cadegianiæ°ã«ãããšãäžåäœã®ç çã¯èšºæãé£ãããä»ã®çŸæ£ã«ãã£ãŠãã¹ã¯ãããããšãå€ããããCOVID-19ã¯ã¯ãã³æ¥çš®åŸã®äžåäœç ççºçŸã«é¢ããæç®ã¯ã»ãšãã©ãªããšã®ããšã§ããã
å¯è
å¯è ã«ãããã¹ãã€ã¯èçœã®å·å®³ã瀺åããæ ¹æ ãšãªãåŸãããŒã¿ãæã€æç®ãçºè¡šãããŠããŸãã
å¯è ã¯ãè èã®äžã«äœçœ®ããã¹ãã¬ã¹åå¿ãæ ããã«ã¢ã³ãç£çããŸããããã«ã¯ãã¢ãã¬ããªã³ãã³ã«ããŸãŒã«ãã¢ã«ãã¹ããã³ãå«ãŸããŸãããã®3ã€ã®ãã«ã¢ã³ã®æŸåºã¯ãã¹ãã¬ã¹ã®å€ãç¶æ³äžã§ãšãã«ã®ãŒããã®ä»ã®å¿ èŠãªãã®ãç¶æããããã«éèŠã§ãã
COVID-19ã«é¢ããç ç©¶ã§ã¯ãå¯è ãSARS-CoV-2 mRNAã®èç©ãšã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ç£çã®äž»èŠãªéšäœã§ããããšã瀺ãããŠããã
ãŸãããã®è ºã¯è¥ãç·æ§ã«ããèŠãããã¯ã¯ãã³æ¥çš®åŸã®å¿çççŸè±¡ã«é¢äžããŠããå¯èœæ§ãé«ããCadegianiã¯ããã®çš®ã®å¿ççã¯å¯è æ©èœé害ã®åŸŽåã§ããå¯èœæ§ããããšçç±ä»ããŠããã
Cadegianiã¯ãã¯ã¯ãã³åŸå¿ççã«é¢ããå°éå®¶ã«ããç ç©¶ãå·çããã«ãã³ãŒã«ã¢ãã³ããããã®äºè±¡ã®äž»ãªåŒãéã§ãããšçµè«ã¥ãããã«ãã³ãŒã«ã¢ãã³ãšã¯ãç¥çµãã«ã¢ã³ã®äžçš®ã§ãããŒããã³ããã«ã¢ãã¬ããªã³ãã¢ãã¬ããªã³ãªã©ãå«ãŸããŸãã
ããŒããã³ã¯äž»ã«ç¥çµç³»ã§äœçšããŸãããã¢ãã¬ããªã³ãšãã«ã¢ãã¬ããªã³ã¯ãšãã«ã¹ãã¬ã¹åå¿ã«éèŠãªåœ¹å²ãæãããŸãã
ã¢ãã¬ããªã³ã¯éäºãŸãã¯éèµ°ã®ã¹ãã¬ã¹åå¿ã掻æ§åãããã«ã¢ãã¬ããªã³ã¯å¿ææ°ã®å¢å ãèèªã®åè§£ãè¡ç³å€ã®äžæã«ãã£ãŠãã®åå¿ããµããŒãããŸãã
æ¿ããéåãé·æéã®éåã¯éäºã»éèµ°åå¿ãèªçºãããããã¹ããŒãéžæã§ã¯éåžžãã«ãã³ãŒã«ã¢ãã³ãé«å€ã§æšç§»ããŸããç¹ã«ç·æ§ã¯ã«ãã³ãŒã«ã¢ãã³ã®æ¿åºŠãé«ãåŸåã«ãããŸãããŸããã¯ã¯ãã³æ¥çš®åŸã«å¿ççã®çºççãé«ããªãã®ããç·æ§ãã«ã¢ã³ã®é¢äžãçãããŠããã
ã¹ãã¬ã¹åå¿ã¯è¡å§ãäžæãããå¿èã®åçž®ã匷ãããæ ¢æ§åãããšå¿çæ¢å¡ã®ãªã¹ã¯ãå¢å€§ãããã
Cadegianiã¯ãmRNAã¯ã¯ãã³æ¥çš®ã®3ã4æ¥åŸã«å¿ççãèµ·ãããŠæ»äº¡ãã2人ã®10代ã®å°å¹Žã®åæ€å ±åãåæããã«ãã³ãŒã«ã¢ãã³ãšå¿ççãé¢é£ã¥ããã
圌ãã®å¿èã®æå·ã¯éåžžã®å¿ççã®ç çãšã¯ç°ãªããã¹ãã¬ã¹ã«ããå¿ççãšã®æãããªé¡äŒŒæ§ãèŠããããCadegianiã¯ã«ãã³ãŒã«ã¢ãã³ã«ããå¿ççã®æç¢ºãªç¹åŸŽã芳å¯ããã
圌ã¯ãã¯ã¯ãã³ãã¢ãã¬ããªã³ã®ã¬ãã«ãäžæãããã¢ãã¬ããªã³ã®é掻æ§åãåŒãèµ·ããããšã«ãã£ãŠãé«ã«ãã³ãŒã«ã¢ãã³æ§ç¶æ ãèªçºãããšãã仮説ãç«ãŠãã
mRNAã¯ã¯ãã³ãæ¥çš®ããã¢ã¹ãªãŒãã察象ãšããç ç©¶ã§ããéååŸãã¯ã¯ãã³ãæ¥çš®ããäººã¯æ¥çš®ããŠããªãäººã«æ¯ã¹ãŠå¿ææ°ãšãã«ã¢ãã¬ããªã³ã¬ãã«ãé«ããªãããšãããã£ãã
å¯è ã®æ©èœäžå šã¯ãå¯è æ©èœäžå šãåŒãèµ·ãããšèããããã
Cadegianiã¯ãã¹ãã€ã¯èçœå·å®³ã®çµæãšããŠãå¯è ãååãªãã«ã¢ã³ãåæ³ã§ããªããªãç¶æ ãããªãã¡å¯è æ©èœäžå šãèµ·ããå¯èœæ§ããããšä»®å®ããã
ãã§ã«ææçã§å¯è æ©èœäžå šã«ãªã£ããšããå ±åããããŸãããã¹ãã€ã¯èçœã®æ®éªžãããé·ãCOVID-19ã®å Žåãé害ãé·åŒããæ ¢æ§é害ã«ãªãå¯èœæ§ããããšèããããŸãã
ã¯ã¯ãã³ã®å ŽåãCOVID-19 mRNAæ¥çš®åŸã®ã¹ãã€ã¯èçœç£çéãè©äŸ¡ããå ±åã«ãããšãå¯è ã¯ã¹ãã€ã¯èçœç£çéã®å€ãçµç¹ã®äžã€ã§ããããã®å¯è ã®ã¹ãã€ã¯èçœç£çéã¯æéãšãšãã«å¢å ããããšãåãã£ãŠããŸãã
ãŸããçŸåšã®ç ç©¶ã§ã¯ãã¯ã¯ãã³æ¥çš®åŸã®çç¶ãšããŠè¡å°æ¿æžå°çãå䜵ããããšã§ãå¯è åºè¡ãå¯è æ©èœäžå šã«è³ãããšãåãã£ãŠããŸãã
ç²ç¶è º
ç²ç¶è ºã¯ãã®ã©ã®äžã«ããè¶ã®åœ¢ãããè ºã§ããå€ãã®æ©èœãæã¡ãäž»ã«æé·ãšä»£è¬ã調ç¯ããŠããŸãã
ç²ç¶è ºã¯ããµã€ããã·ã³ãšããªãšãŒããµã€ããã³ãšãã2ã€ã®ãã«ã¢ã³ãäœã£ãŠããŸããããªãšãŒããµã€ããã³ãäžè¶³ãããšç²ç¶è ºæ©èœäœäžçã«ãªããç²ç¶è ºã倧ãããªãã®ãç¹åŸŽã§ãéå°ã«åæ³ããããšç²ç¶è ºæ©èœäº¢é²çã«ãªãããšããããŸãã
ãŸããç²ç¶è ºã¯å ç«ç³»ã®èª¿ç¯ã«ãé¢äžããŠããŸããCOVID-19ææçã¯ããã°ãã°ç²ç¶è ºã®åºç€çŸæ£ã®å åã§ãããææçã«ãããã¡ãŒãžã¯ç²ç¶è ºã®åé¡ãæªåãããè² ã®é£éãçã¿åºããŸãã
COVID-19ã§æ»äº¡ãã15人ã®åæ€èª¿æ»ã«ãããšããã®ãã¡13人ã®ç²ç¶è ºçµç¹ã«ãŠã€ã«ã¹ã®RNAãšã¿ã³ãã¯è³ªãæ€åºãããŸããããŸããç²ç¶è ºã«ã¯ååšããªããšèããããŠããACE2ã¬ã»ãã¿ãŒãæ€åºãããSARS-CoV-2ã®ææçµè·¯ã®å¯èœæ§ã瀺ãããã
ãã®ç ç©¶ã«ãããç²ç¶è ºãææã«é¢äžããããšã瀺ãããããç²ç¶è ºã®ççã§ããç²ç¶è ºçã¯ãçŸåšã®ãšãããCOVID-19ã¯ã¯ãã³ãšã®é¢é£ã§ããå ±åãããŠããªãã
ãã«ã³ã®ç ç©¶ã§ã¯ãCOVID-19ã¯ã¯ãã³ãç²ç¶è ºçãèªçºããå¯èœæ§ããããšè¿°ã¹ãããŠããŸãããã®ç ç©¶ã§ã¯ãã¯ã¯ãã³æ¥çš®åŸã«ç²ç¶è ºçãçºçãã15äººã®æ£è ãè©äŸ¡ããŸããã
æ£è ã®ãã¡4人ã¯ãèªå·±å ç«çŸæ£ã§ããç²ç¶è ºæ©èœäº¢é²çã®å䜵çã§ããã°ã¬ãŒãç ãçºçããŸããããŸããå¥ã®ç²ç¶è ºèªå·±å ç«çŸæ£ã§ããæ©æ¬ç ããã¯ã¯ãã³æ¥çš®åŸã«å ±åãããŠããã
äºé²æ¥çš®ã§äœãããã¹ãã€ã¯ç¶ã®ã¿ã³ãã¯è³ªããACE2å容äœã«çµåããŠç²ç¶è ºçްèãæ»æããŠããå¯èœæ§ãããã®ã§ããããããèªå·±å ç«çŸæ£ã®å ±åãå€ãããšãããCadegianiã¯ãç²ç¶è ºæ©èœé害ã®ç æ ã¯èªå·±å ç«çŸæ£ã§ããå¯èœæ§ãé«ããšæšæž¬ããŠããã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ã"ååæš¡å£ "ã®çºçé »åºŠãé«ãããšãããèªå·±å ç«èœåãå®èšŒããŠããã
èµè
èµèã¯ãã°ã«ã«ãŽã³ãšã€ã³ã¹ãªã³ãšããè¡ç³å€ã調ç¯ããéèŠãªãã«ã¢ã³ãåæ³ããŠããŸããè¡ç³å€ã®èª¿ç¯é害ã¯ãèµèã®æ©èœé害ã®å åã§ãããç³å°¿ç ãªã©ã®å䜵çã«ã€ãªããå¯èœæ§ããããŸãã
ã¯ã¯ãã³ãšãŠã€ã«ã¹ã®äž¡æ¹ã«å«ãŸããã¹ãã€ã¯ã¿ã³ãã¯ã¯ãç³ä»£è¬ãä¹±ãå¯èœæ§ã瀺ããŠããŸãã
ãŸããèªå·±å ç«çŸæ£ã®äžã€ã§ãã1åç³å°¿ç ã¯ãèªåã®èµèã®Î²çްèãæ»æããŠããŸããããçªç¶çºçããããšãå ±åãããŠããŸãã
ãŸããEudraVigilanceã®å®å šæ§ç£èŠå ±åãè©äŸ¡ããç ç©¶ã§ã¯ãã¯ã¯ãã³æ¥çš®åŸã«äžéæ§ã®é«è¡ç³ã®æªåã䌎ãè¡ç³èª¿ç¯ç°åžžãå ±åãããŠããããšãåãã£ãŠããŸãã
æ ¢æ§çãªé«è¡ç³ãã€ãŸãè¡ç³å€ãé«ãç¶æ ã¯ãéåžžãèµèã®Î²çްèã®æ©èœé害ã®ãµã€ã³ã§ããã
ããã§Cadegianiã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãèµèã®Î²çްèã«çŽæ¥äœçšããŠæå·ãäžãããã®çµæãèµèã®Î²çްèãæ»æ» ããå¯èœæ§ãããããšãç ç©¶ããŠãèµèã®Î²çްèã®æå€±ãæ©èœäžå šã®å¯èœæ§ãææ¡ããã
çæ®åšå®
COVID-19ã®ç·æ§çæ®åšãžã®å®³ã¯ããç¥ãããŠããŸãã
ã¿ã€ã®ç ç©¶ã§ã¯ãæ§çã«æŽ»çºãªç·æ§153人ã«ãããŠãçŽ64.7%ãCOVID-19æææã«åèµ·äžå šãçµéšããå埩åŸ3ã«æçµéããŠã50%ããã®çç¶ãæç¶ããŠããããšã瀺ãããŠããŸãã
åèµ·äžå šã¯å ç®çްèã®æ©èœé害ã«èµ·å ããããšãç ç©¶ã«ãã確ç«ãããŠãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯å ç®çްèãé害ããã
COVID-19ãšåèµ·äžå šãé¢é£ä»ããç ç©¶ã§ã¯ãå ç®çްèã®è¡šé¢ã«è¡šç€ºãããACE2å容äœãšãŠã€ã«ã¹ãçžäºäœçšããããšã倧ããªåå ãšãªã£ãŠãããå ç®çްèã«ã¯ACE2å容äœãå€ãååšããCOVID-19ã®ææã§æãæšçãšããã现èã®äžã€ãšãªã£ãŠããã
ã¢ãããŠã€ã«ã¹DNAã¯ã¯ãã³ãè©äŸ¡ããç ç©¶ã§ã¯ãã¯ã¯ãã³ã«ããããã现èã¯ãACE2å容äœãšçžäºäœçšããŠçµåã§ããã¹ãã€ã¯ã¿ã³ãã¯è³ªãçæããå ç®ã®æå·ãçããããšã瀺åãããã
2021幎ã«ã¯ã¯ãã³ãå±éãããŠä»¥æ¥ãCDCã®ããŒã¿ã§ã¯COVID-19ã¯ã¯ãã³æ¥çš®åŸã®åèµ·äžå šã193äŸå ±åãããŠããŸãã
ãŸãã粟åæäŸã«é¢ããã€ã¹ã©ãšã«ã®ç ç©¶ã§ã¯ãCOVID-19 mRNAã¯ã¯ãã³æ¥çš®åŸã«ç²Ÿåæ¿åºŠã15ïŒ ãéåæ§ç²Ÿåæ°ã22ïŒ æžå°ããããšã泚ç®ãããŠããã
èè ãã¯åŸã®åçã§ããã¹ãããã人ã ã«ã¯åºç€çŸæ£ããªãã£ããããã¯ã¯ãã³æ¥çš®åã«ååšããåºç€çŸæ£ã«ããæžå°ã§ã¯ãªãããšã確èªããŸããã
145æ¥åŸã«ç²Ÿåæ°ã¯åŸã ã«å埩ãããã®ã®ãç²Ÿåæ¿åºŠãéåçã¯ã¯ã¯ãã³æ¥çš®åã®ã¬ãã«ã«ã¯æ»ãããé·æçãªåœ±é¿ã¯äžæã§ãã£ãã
ãŸãã女æ§ã«ãããŠããç¹ã«ææåŸãããã¯ã¯ãã³æ¥çš®åŸã«çæ®æ©èœã®åé¡ãæžå¿µãããããšãå ±åãããŠããŸãã
ç ç©¶ã«ãããšãäžè¬çã«ç·æ§ã¯COVID-19ææã«ããé節ãªçµæãæ»äº¡ã®ãªã¹ã¯ãé«ããã女æ§ã¯ã¯ã¯ãã³å·å®³ã®ãªã¹ã¯ãé«ãããã§ããã
ã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã ïŒVAERSïŒã®ããŒã¿ã§ã¯ãæå®³äºè±¡å ±åã®60%以äžã女æ§ããã§ããã女æ§ãã¯ã¯ãã³åŸã®çç¶ã«å¯ŸããŠããè匱ã§ããããšã瀺ããŠããŸãã
ãŸããã¯ãªãã£ã«ã«ã±ã¢ã®å°éå®¶ã§ããPaul Marikå士ã¯ã女æ§ãã¯ãªããã¯ã§ã¯ã¯ãã³åŸéºçãåãããªã¹ã¯ãé«ãããšã芳å¯ããŠããŸãã
ãã³ãããã¯ã®éãå€ãã®å¥³æ§ãã¯ã¯ãã³æ¥çš®åŸã«æçµç°åžžã蚎ããŸãããäžæ±ã®å¥³æ§ã察象ã«ãã調æ»ã§ã¯ã7å²è¿ããã¯ã¯ãã³æ¥çš®åŸã«æçµç°åžžã蚎ãããšããã
åœç«è¡çç ç©¶æãè³éæäŸããç ç©¶ã§ã¯ãCOVID-19ã®ã¯ã¯ãã³æ¥çš®ã«é¢é£ããŠãæçµåšæã®é·ããäžæçã«é·ããªããããšã倿ããŠããŸãã
My Cycle Storyãšé¡ããããŠã§ããµã€ãã«æ²èŒãããç ç©¶ã§ã¯ãéå»109幎éã§ãã®ãããªã±ãŒã¹ã40件以äžã§ããã«ãããããããCOVID-19ã¯ã¯ãã³ã®å±éåŸã«290人以äžã®å¥³æ§ãè±å¢ãçµéšãããšå ±åãããŠããŸãã
ãŸãã女æ§ãèŠããã§ããçæ®åšç³»ã®çç¶ã®å€ãã¯ãCOVID-19ææãšé¢ä¿ããããšãããããããããã¯ã¯ãã³ãšé¢ä¿ãããå¯èœæ§ãããããšã瀺ãããŸããã
Cadegianiã¯ãä»åŸãåŠåš äžã®æå®³äºè±¡ãããå€ãçºçããããšãäºæž¬ããã
圌ã¯ãCOVID-19ã¯ã¯ãã³ãšçæ®èœåãšã®éã«ãé¢é£æ§ã¯ãªãããšçµè«ã¥ããç ç©¶ãåŒçšãããããããã¯ã¯ãã³æªæ¥çš®ã®å¥³æ§ã¯ã¯ã¯ãã³æ¥çš®è ãããèšåºçãçååŠçãªåŠåš ã®å²åãé«ããšããããŒã¿ã§ãã£ãã
è«æã®èè ãã¯10ä»¶ã®ç ç©¶ãã¬ãã¥ãŒããã¯ã¯ãã³æªæ¥çš®ã®å¥³æ§ã¯èšåºçåŠåš çã47ïŒ ãçååŠçåŠåš çã60ïŒ ã§ããã®ã«å¯ŸããCOVID-19ã¯ã¯ãã³æ¥çš®è ã¯45ïŒ ãš51ïŒ ã§ããããšãæããã«ããã
Cadegianiã¯ãä»åŸãã¹ãã€ã¯ã®å·å®³ã«ããå åæ³çŸæ£ã®çäŸãå¢ãããšäºæž¬ããŠããã
"å åæ³çŸæ£ã¯ãã£ãããšé²è¡ãããããŠéçã®ç¶æ ã«ãªã£ãŠåããŠèšåºçã«çŸãã "ãšCadegianiã¯èšã£ãã"ã ããããããïŒãã€ã§ãïŒäºåã«äŒããããšã¯äžå¯èœãªã®ã§ãã"
The Epoch Timesã®èš±å¯ãåŸãŠè»¢èŒããŠããŸãã
Marina Zhangã¯ããã¥ãŒãšãŒã¯ãæ ç¹ã«ãThe Epoch Timesã®ããã«å¥åº·ãšç§åŠãã«ããŒããŠããŸãã
ãã®èšäºã§ç€ºãããèŠè§£ãæèŠã¯èè ã®ãã®ã§ãããå¿ ãããChildren's Health Defenseã®èŠè§£ãåæ ãããã®ã§ã¯ãããŸããã